Alpha Cognition Inc (ACOG.CA) Stock Price & Overview
TSX-V:ACOG • CA02074J2048
Current stock price
The current stock price of ACOG.CA is 0.39 CAD. Today ACOG.CA is down by -14.29%. In the past month the price increased by 11.43%. In the past year, price decreased by -37.1%.
ACOG.CA Key Statistics
- Market Cap
- 33.891M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.22
- Dividend Yield
- N/A
ACOG.CA Stock Performance
ACOG.CA Stock Chart
ACOG.CA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ACOG.CA. When comparing the yearly performance of all stocks, ACOG.CA turns out to be only a medium performer in the overall market: it outperformed 64.51% of all stocks.
ACOG.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACOG.CA. ACOG.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
ACOG.CA Earnings
ACOG.CA Forecast & Estimates
6 analysts have analysed ACOG.CA and the average price target is 3.06 CAD. This implies a price increase of 684.62% is expected in the next year compared to the current price of 0.39.
ACOG.CA Groups
Sector & Classification
ACOG.CA Financial Highlights
Over the last trailing twelve months ACOG.CA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 12.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -239.04% | ||
| ROE | -839.02% | ||
| Debt/Equity | 0.89 |
ACOG.CA Ownership
ACOG.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 603.696M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 401.985M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 148.177M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.18 | 52.478M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 47.549M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 36.975M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.47 | 33.815M | ||
| RVX | RESVERLOGIX CORP | N/A | 31.617M | ||
| MPH | MEDICURE INC | N/A | 14.094M | ||
| HEM | HEMOSTEMIX INC | N/A | 11.867M | ||
| CSCI | COSCIENS BIOPHARMA INC | N/A | 8.459M | ||
| KNE | KANE BIOTECH INC | N/A | 6.365M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About ACOG.CA
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
Company Info
IPO: 2018-09-19
Alpha Cognition Inc
301 - 1228 Hamilton Street, Null
Vancouver BRITISH COLUMBIA V6B 2E6 CA
CEO: Michael McFadden
Employees: 0
Phone: 16045649244.0
Alpha Cognition Inc / ACOG.CA FAQ
Can you describe the business of Alpha Cognition Inc?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-09-19. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
What is the stock price of Alpha Cognition Inc today?
The current stock price of ACOG.CA is 0.39 CAD. The price decreased by -14.29% in the last trading session.
Does ACOG stock pay dividends?
ACOG.CA does not pay a dividend.
How is the ChartMill rating for Alpha Cognition Inc?
ACOG.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is ACOG.CA stock listed?
ACOG.CA stock is listed on the TSX Venture Exchange exchange.
Can you provide the market cap for Alpha Cognition Inc?
Alpha Cognition Inc (ACOG.CA) has a market capitalization of 33.89M CAD. This makes ACOG.CA a Nano Cap stock.